Moreover, it has been speculated that the p16Ink4A alteration in lung cancer is a rather early event that may accelerate tumor aggressiveness through inactivation of both the RB and p53 pathways and may link to a poor disease outcome [16, 18, 19, 44]. The gene discussed is CDKN2A; the disease is neoplasm.